|
1
|
Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas.
|
Cancer Cell
|
2007
|
5.40
|
|
2
|
Oncogenic role of miR-483-3p at the IGF2/483 locus.
|
Cancer Res
|
2010
|
2.30
|
|
3
|
MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells.
|
Cancer Res
|
2010
|
2.28
|
|
4
|
In hepatocellular carcinoma miR-519d is up-regulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2.
|
J Pathol
|
2012
|
2.27
|
|
5
|
MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells.
|
Cancer Res
|
2009
|
2.16
|
|
6
|
Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model.
|
Hepatology
|
2012
|
1.23
|
|
7
|
Frequent aberrant methylation of the CDH4 gene promoter in human colorectal and gastric cancer.
|
Cancer Res
|
2004
|
1.21
|
|
8
|
Selective ablation of Notch3 in HCC enhances doxorubicin's death promoting effect by a p53 dependent mechanism.
|
J Hepatol
|
2009
|
1.14
|
|
9
|
Hepatocellular carcinoma: epidemiology and clinical aspects.
|
Mol Aspects Med
|
2007
|
1.14
|
|
10
|
Mutated beta-catenin evades a microRNA-dependent regulatory loop.
|
Proc Natl Acad Sci U S A
|
2011
|
1.08
|
|
11
|
microRNA involvement in hepatocellular carcinoma.
|
Anticancer Agents Med Chem
|
2011
|
1.06
|
|
12
|
Role of microRNAs in hepatocellular carcinoma: a clinical perspective.
|
Onco Targets Ther
|
2013
|
1.02
|
|
13
|
Multigene methylation analysis of gastrointestinal tumors: TPEF emerges as a frequent tumor-specific aberrantly methylated marker that can be detected in peripheral blood.
|
Mol Diagn
|
2003
|
0.96
|
|
14
|
Significance of serum and hepatic microRNA-122 levels in patients with non-alcoholic fatty liver disease.
|
Liver Int
|
2014
|
0.96
|
|
15
|
Loss of methylation at chromosome 11p15.5 is common in human adult tumors.
|
Oncogene
|
2002
|
0.95
|
|
16
|
From liver cirrhosis to HCC.
|
Intern Emerg Med
|
2011
|
0.95
|
|
17
|
CDKN1C/P57 is regulated by the Notch target gene Hes1 and induces senescence in human hepatocellular carcinoma.
|
Am J Pathol
|
2012
|
0.93
|
|
18
|
Anti-tumor activity of a miR-199-dependent oncolytic adenovirus.
|
PLoS One
|
2013
|
0.93
|
|
19
|
Notch3 intracellular domain accumulates in HepG2 cell line.
|
Anticancer Res
|
2006
|
0.91
|
|
20
|
Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3b phosphorylation and p21 down-regulation in hepatocellular carcinoma.
|
Oncotarget
|
2013
|
0.91
|
|
21
|
Oxidative stress EPR measurement in human liver by radical-probe technique. Correlation with etiology, histology and cell proliferation.
|
Free Radic Res
|
2002
|
0.90
|
|
22
|
The natural inhibitor of DNA topoisomerase I, camptothecin, modulates HIF-1α activity by changing miR expression patterns in human cancer cells.
|
Mol Cancer Ther
|
2013
|
0.89
|
|
23
|
Local hypothyroidism favors the progression of preneoplastic lesions to hepatocellular carcinoma in rats.
|
Hepatology
|
2014
|
0.89
|
|
24
|
miR-221 affects multiple cancer pathways by modulating the level of hundreds messenger RNAs.
|
Front Genet
|
2013
|
0.89
|
|
25
|
Serum albumin-bound proteomic signature for early detection and staging of hepatocarcinoma: sample variability and data classification.
|
Clin Chem Lab Med
|
2010
|
0.85
|
|
26
|
p53/mdm2 feedback loop sustains miR-221 expression and dictates the response to anticancer treatments in hepatocellular carcinoma.
|
Mol Cancer Res
|
2013
|
0.84
|
|
27
|
MicroRNA response to environmental mutagens in liver.
|
Mutat Res
|
2011
|
0.83
|
|
28
|
Human hepatocellular carcinoma expresses specific PCNA isoforms: an in vivo and in vitro evaluation.
|
Lab Invest
|
2008
|
0.83
|
|
29
|
Liver metastases from rectal carcinoma: disease progression during chemotherapy despite loss of arterial-phase hypervascularity on real-time contrast-enhanced harmonic sonography at low acoustic energy.
|
J Clin Ultrasound
|
2003
|
0.77
|
|
30
|
Checkpoint effectors CDKN1A and Gadd45 correlate with oxidative DNA damage in human prostate carcinoma.
|
Anticancer Res
|
2005
|
0.75
|
|
31
|
Design, synthesis and biological evaluation of pyrazole derivatives as potential multi-kinase inhibitors in hepatocellular carcinoma.
|
Eur J Med Chem
|
2011
|
0.75
|